Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Silence Therapeutics Plc - American Depository Share
(NQ:
SLN
)
6.370
+0.140 (+2.25%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Silence Therapeutics Plc - American Depository Share
< Previous
1
2
3
Next >
Bausch Health’s Slow Rebuild Faces New Scrutiny After Lombard Odier Cuts Its Stake
↗
December 10, 2025
Bausch Health’s valuation suggests potential, but the stake cut shows how far the company still has to go to earn back full investor confidence.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 21, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 21, 2025
Via
Benzinga
Silence (SLN) Q2 Revenue Drops 71%
↗
August 07, 2025
Via
The Motley Fool
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
↗
March 04, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
↗
February 03, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 03, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 13, 2025
Via
Benzinga
These stocks are moving in today's pre-market session
↗
April 01, 2025
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Via
Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15
↗
February 15, 2025
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.
Via
Talk Markets
Topics
Stocks / Equities
The Analyst Landscape: 6 Takes On Silence Therapeutics
↗
December 10, 2024
Via
Benzinga
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
↗
November 15, 2024
Via
Benzinga
Analyst Expectations For Silence Therapeutics's Future
↗
August 16, 2024
Via
Benzinga
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
February 11, 2025
Via
Benzinga
Top 3 Health Care Stocks That May Explode In Q4
↗
December 18, 2024
Via
Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
↗
November 19, 2024
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
Via
Benzinga
Top 3 Health Care Stocks You'll Regret Missing In Q4
↗
November 19, 2024
Via
Benzinga
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
↗
August 15, 2024
Silence Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
↗
August 07, 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Via
InvestorPlace
The Analyst Landscape: 6 Takes On Silence Therapeutics
↗
June 20, 2024
Via
Benzinga
What 7 Analyst Ratings Have To Say About Silence Therapeutics
↗
May 17, 2024
Via
Benzinga
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
↗
April 22, 2024
Via
Benzinga
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
↗
July 25, 2024
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
Via
InvestorPlace
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
↗
May 16, 2024
Silence Therapeutics just reported results for the first quarter of 2024.
Via
InvestorPlace
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
↗
April 11, 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Via
InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
↗
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
↗
March 14, 2024
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Silence Therapeutics
↗
March 13, 2024
Via
Benzinga
What's Going On With Silence Therapeutics Stock Today?
↗
March 13, 2024
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of...
Via
Benzinga
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today